BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 16721125)

  • 1. The prevention of febrile neutropenia.
    Pascoe J; Cullen M
    Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider.
    Lo N; Cullen M
    Hematol Oncol; 2006 Sep; 24(3):120-5. PubMed ID: 16783844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic factors for febrile neutropenia].
    Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
    Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics for the prevention of febrile neutropenia.
    Pascoe J; Steven N
    Curr Opin Hematol; 2009 Jan; 16(1):48-52. PubMed ID: 19057204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of febrile neutropenia: use of prophylactic antibiotics.
    Cullen M; Baijal S
    Br J Cancer; 2009 Sep; 101 Suppl 1(Suppl 1):S11-4. PubMed ID: 19756000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
    J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
    Wingard JR; Elmongy M
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
    Johnston EM; Crawford J
    Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.